更短的结核病治疗方案也应该更安全。

IF 1.3 Q4 RESPIRATORY SYSTEM

Public Health Action Pub Date : 2023-09-21 DOI:10.5588/pha.23.0026

O Rucsineanu, P Agbassi, R Herrera, M Low, L McKenna, J Stillo, P Winarni, A Acharya, A H Sari

{"title":"更短的结核病治疗方案也应该更安全。","authors":"O Rucsineanu, P Agbassi, R Herrera, M Low, L McKenna, J Stillo, P Winarni, A Acharya, A H Sari","doi":"10.5588/pha.23.0026","DOIUrl":null,"url":null,"abstract":"Most ongoing and planned TB therapeutic trials are focused on shortening the duration of treatment while giving less consideration to other aspects of TB care that are important to people with TB. Here we argue that other variables besides duration of TB treatment should also be considered when developing new TB treatment regimens, including drug toxicity, time spent in monitoring and overall quality of life while on therapy. We examine the specific use of linezolid in treatment-shortening trials for drug-susceptible TB and propose additional endpoints that should be prioritised in TB treatment studies.","PeriodicalId":46239,"journal":{"name":"Public Health Action","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446660/pdf/","citationCount":"0","resultStr":"{\"title\":\"Shorter TB treatment regimens should be safer as well.\",\"authors\":\"O Rucsineanu, P Agbassi, R Herrera, M Low, L McKenna, J Stillo, P Winarni, A Acharya, A H Sari\",\"doi\":\"10.5588/pha.23.0026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Most ongoing and planned TB therapeutic trials are focused on shortening the duration of treatment while giving less consideration to other aspects of TB care that are important to people with TB. Here we argue that other variables besides duration of TB treatment should also be considered when developing new TB treatment regimens, including drug toxicity, time spent in monitoring and overall quality of life while on therapy. We examine the specific use of linezolid in treatment-shortening trials for drug-susceptible TB and propose additional endpoints that should be prioritised in TB treatment studies.\",\"PeriodicalId\":46239,\"journal\":{\"name\":\"Public Health Action\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2023-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446660/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Public Health Action\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5588/pha.23.0026\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health Action","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/pha.23.0026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

大多数正在进行和计划中的结核病治疗试验都侧重于缩短治疗时间，而较少考虑对结核病患者重要的结核病护理的其他方面。在这里，我们认为，在制定新的结核病治疗方案时，除了结核病治疗的持续时间外，还应该考虑其他变量，包括药物毒性、监测时间和治疗期间的总体生活质量。我们研究了利奈唑胺在药物敏感结核病缩短治疗试验中的具体用途，并提出了结核病治疗研究中应优先考虑的其他终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Shorter TB treatment regimens should be safer as well.

Most ongoing and planned TB therapeutic trials are focused on shortening the duration of treatment while giving less consideration to other aspects of TB care that are important to people with TB. Here we argue that other variables besides duration of TB treatment should also be considered when developing new TB treatment regimens, including drug toxicity, time spent in monitoring and overall quality of life while on therapy. We examine the specific use of linezolid in treatment-shortening trials for drug-susceptible TB and propose additional endpoints that should be prioritised in TB treatment studies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Public Health Action RESPIRATORY SYSTEM-

自引率

0.00%

发文量

期刊介绍： Launched on 1 May 2011, Public Health Action (PHA) is an official publication of the International Union Against Tuberculosis and Lung Disease (The Union). It is an open access, online journal available world-wide to physicians, health workers, researchers, professors, students and decision-makers, including public health centres, medical, university and pharmaceutical libraries, hospitals, clinics, foundations and institutions. PHA is a peer-reviewed scholarly journal that actively encourages, communicates and reports new knowledge, dialogue and controversy in health systems and services for people in vulnerable and resource-limited communities — all topics that reflect the mission of The Union, Health solutions for the poor.